Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

DrugPatentWatch Database Preview

Details for Patent: 8,420,592

« Back to Dashboard

Which drugs does patent 8,420,592 protect, and when does it expire?

Patent 8,420,592 protects ORBACTIV and is included in one NDA.

This patent has seventeen patent family members in fifteen countries.

Summary for Patent: 8,420,592

Title:Methods of treatment using single doses of oritavancin
Abstract: Glycopeptide antibiotics, such as oritavancin, demonstrate significant activity against a wide range of bacteria. Methods for the treatment, prophylaxis and prevention of bacterial infection and disease in animals, including humans, using a single dose of oritavancin over the course of therapy, are described.
Inventor(s): Lehoux; Dario (Terrebonne, CA), Parr; Thomas R. (Indianapolis, IN), Moeck; Gregory (St. Laurent, CA), Etienne; Pierre (Montreal, CA)
Assignee: The Medicines Company (Parsippany, NJ)
Application Number:13/060,811
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form;

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
The Medicines Co
ORBACTIV
oritavancin diphosphate
POWDER;IV (INFUSION)206334-001Aug 6, 2014RXYesYes8,420,592► Subscribe TREATMENT OF BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS USING A SINGLE DOSE
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 8,420,592

PCT Information
PCT FiledAugust 29, 2009PCT Application Number:PCT/US2009/055466
PCT Publication Date:March 04, 2010PCT Publication Number: WO2010/025438

International Patent Family for Patent: 8,420,592

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
China102215858► Subscribe
Denmark2337575► Subscribe
Eurasian Patent Organization201100413► Subscribe
Eurasian Patent Organization020490► Subscribe
European Patent Office2337575► Subscribe300834Netherlands► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc